Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . Brii Biosciences Breakthrough innovation & insight Brii Biosciences Limited 腾 盛 博 药 生物 科技 有限公司 ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 2137 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2021 The board of directors ( the “ Board ” ) of Brii Biosciences Limited ( the “ Company ” ) is pleased to announce the unaudited condensed consolidated interim results of the Company and its subsidiaries ( collectively , the “ Group ” , “ we ” or “ us ” ) for the six months ended June 30 , 2021 , together with the comparative figures for the previous year . Unless otherwise defined herein , capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus of the Company dated June 30 , 2021 ( the “ Prospectus ” ) . FINANCIAL HIGHLIGHTS Other income was RMB46.3 million for the six months ended June 30 , 2021 , representing an increase of RMB23.4 million or 102.2 % , compared with RMB22.9 million for the six months ended June 30 , 2020. The increase was mainly attributable to the increased income recognized from government grants . R & D expenses were RMB157.6 million for the six months ended June 30 , 2021 , representing a decrease of RMB108.1 million or 40.7 % , compared with RMB265.7 million for the six months ended June 30 , 2020. The decrease was primarily due to the decrease of RMB134.2 million in licensing fees . Administrative expenses were RMB68.0 million for the six months ended June 30 , 2021 , representing an increase of RMB26.8 million or 65.0 % , compared with RMB41.2 million for the six months ended June 30 , 2020. The increase was primarily attributable to the increase in employee headcount . Total comprehensive expense for the six months ended June 30 , 2021 was RMB2,921.5 million , representing an increase of RMB2,628.0 million or 895.4 % , compared with RMB293.5 million for the six months ended June 30 , 2020. The increase was primarily attributable to the increase in fair value loss on financial liabilities at FVTPL . 1